HIF prolyl-hydroxylase inhibitor

Class of drugs that inhibit HIF prolyl-hydroxylase enzymes

HIF Prolyl-Hydroxylase Inhibitors

Chemical structure of Roxadustat, a HIF prolyl-hydroxylase inhibitor

HIF prolyl-hydroxylase inhibitors are a class of drugs that target the hypoxia-inducible factor (HIF) pathway by inhibiting the activity of prolyl-hydroxylase enzymes. These enzymes are responsible for the hydroxylation of HIF, which marks it for degradation under normal oxygen conditions. By inhibiting these enzymes, HIF prolyl-hydroxylase inhibitors stabilize HIF, allowing it to accumulate and activate the transcription of genes involved in the response to hypoxia.

Mechanism of Action

Under normal oxygen conditions, HIF is hydroxylated by prolyl-hydroxylase enzymes, which leads to its recognition by the von Hippel-Lindau (VHL) protein and subsequent degradation via the ubiquitin-proteasome system. HIF prolyl-hydroxylase inhibitors prevent this hydroxylation, thereby stabilizing HIF and allowing it to translocate to the nucleus. In the nucleus, HIF acts as a transcription factor, promoting the expression of genes that facilitate adaptation to low oxygen conditions, such as those involved in erythropoiesis, angiogenesis, and metabolism.

Clinical Applications

HIF prolyl-hydroxylase inhibitors are primarily being developed for the treatment of anemia associated with chronic kidney disease (CKD). By stabilizing HIF, these drugs increase the production of erythropoietin, a hormone that stimulates the production of red blood cells. This can help alleviate anemia in patients with CKD, who often have reduced erythropoietin production due to impaired kidney function.

Examples of HIF Prolyl-Hydroxylase Inhibitors

Several HIF prolyl-hydroxylase inhibitors are in various stages of development and clinical use. One of the most well-known is Roxadustat, which has been approved for use in some countries for the treatment of anemia in CKD patients. Other inhibitors in development include daprodustat and vadadustat.

Potential Side Effects

As with any pharmacological treatment, HIF prolyl-hydroxylase inhibitors may have side effects. Potential adverse effects include increased risk of thrombosis, hypertension, and effects on iron metabolism. Long-term safety data are still being collected as these drugs are relatively new to the market.

Research and Development

Research into HIF prolyl-hydroxylase inhibitors is ongoing, with studies exploring their potential applications beyond anemia treatment. These include potential roles in treating ischemic conditions, certain cancers, and other diseases where modulation of the hypoxia response could be beneficial.

Related Pages

• Hypoxia-inducible factor
• Erythropoiesis
• Chronic kidney disease
• Anemia